1. Tenzing 7 delivery catheter with or without a leading microwire for single pass aspiration thrombectomy: A multicenter experience.
- Author
-
Tonetti DA, Koneru M, Bhattacharyya M, English JD, Settecase F, Kim WT, Khalife J, Patel P, Thomas A, Jovin T, Hanel R, Benalia VHC, Cortez GM, Aghaebrahim A, Sauvageau E, Abdalkader M, Nguyen TN, Klein P, Dmytriw AA, and Shaikh H
- Abstract
Introduction: Aspiration mechanical thrombectomy traditionally includes use of an inner microcatheter and leading microwire to navigate an aspiration catheter (AC) to the site of occlusion. Early clinical experience suggests that a leading microwire is often not needed with the Tenzing 7 (T7, Route 92 Medical, San Mateo, CA), a soft tapered tip ledge-reducing delivery catheter. This multicenter experience aims to describe AC delivery success in single-pass thrombectomy using T7 with and without a leading microwire., Methods: A retrospective review was conducted of consecutive patients who underwent single-pass thrombectomy with T7 at six institutions between 2020 and 2022. We examined the percentage of successful AC delivery, puncture-to-revascularization time, and procedural complication rate., Results: A leading microwire with T7 was used in 19/89 (21%) of patients, and it was not used with T7 in 70/89 (79%) of patients. Successful AC delivery was similar with and without microwires (97% vs. 90%, p = 0.15). Median puncture-to-revascularization times were similar (17 min microwire vs. 16 min no-microwire, p = 0.12). No complications were associated with microwire use; one (1.4%) patient had a T7-related vasospasm resolved with verapamil during thrombectomy without a leading microwire. Differences in complication rates were not statistically significant (p = 0.46)., Conclusion: In our real-world clinical experience, leading microwire use was infrequently necessary with the T7 delivery catheter. Successful AC delivery and complication rates were similar with and without microwire use in single-pass T7 thrombectomies. Initial pass with T7 may be performed without use of leading microwire, reserving microwire use for refractory cases or known difficult-to-navigate vasculature., Competing Interests: Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J. English is a consultant for Route 92 Medical and Stryker. He has equity in Route 92 Medical. F. Settecase is a consultant for Route 92 Medical and Stryker. He has received honorarium from Stryker. W. Kim is a consultant for Route 92 Medical and Stryker. He has equity in Route 92 Medical. A. Thomas is a consultant for Stryker, Medtronic, and CereVasc. T. Jovin is a consultant for Anaconda, Route 92 Medical,Viz.AI, FreeOx, Blockade Medical, and Methinks. He serves in an advisory capacity for Cerenovus and Contego Medical. He has equity in Cornidus. He receives research support from Medtronic and Stryker. R. Hanel is a consultant for Medtronic, Stryker, Cerenovous, Microvention, Balt, Phenox, Rapid Medical, and Q'Apel. He serves in an advisory capacity for MiVI, eLum, Three Rivers, Shape Medical, and Cornidus. He receives research support from National Institutes of Health, Interline Endowment, Microvention, Stryker, and CNX. He has equity in InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical Inc., Scientia, RisT, BlinkTBI, and Cornidus. A. Aghaebrahim serves in an advisory capacity for iSchemaView. E. Sauvageau is a consultant for Stryker. T.N. Nguyen serves in an advisory capacity for Vesalio, National Institutes of Health, Avania, Idorsia, Brainomix, and SUMMIT Max PI. She serves as an editor, associate editor, or editorial advisory board member for the American Heart Association. She receives research support from Society of Vascular and Interventional Neurology and Boston Medical Center. All other authors have no disclosures to declare..
- Published
- 2023
- Full Text
- View/download PDF